Online citations, reference lists, and bibliographies.

Blood-pressure Targets In Patients With Recent Lacunar Stroke: The SPS3 Randomised Trial

O. Benavente, C. Coffey, R. Conwit, R. Hart, L. McClure, L. Pearce, P. Pergola, J. Szychowski
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Lowering of blood pressure prevents stroke but optimum target levels to prevent recurrent stroke are unknown. We investigated the effects of different blood-pressure targets on the rate of recurrent stroke in patients with recent lacunar stroke. METHODS In this randomised open-label trial, eligible patients lived in North America, Latin America, and Spain and had recent, MRI-defined symptomatic lacunar infarctions. Patients were recruited between March, 2003, and April, 2011, and randomly assigned, according to a two-by-two multifactorial design, to a systolic-blood-pressure target of 130-149 mm Hg or less than 130 mm Hg. The primary endpoint was reduction in all stroke (including ischaemic strokes and intracranial haemorrhages). Analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT 00059306. FINDINGS 3020 enrolled patients, 1519 in the higher-target group and 1501 in the lower-target group, were followed up for a mean of 3·7 (SD 2·0) years. Mean age was 63 (SD 11) years. After 1 year, mean systolic blood pressure was 138 mm Hg (95% CI 137-139) in the higher-target group and 127 mm Hg (95% CI 126-128) in the lower-target group. Non-significant rate reductions were seen for all stroke (hazard ratio 0·81, 95% CI 0·64-1·03, p=0·08), disabling or fatal stroke (0·81, 0·53-1·23, p=0·32), and the composite outcome of myocardial infarction or vascular death (0·84, 0·68-1·04, p=0·32) with the lower target. The rate of intracerebral haemorrhage was reduced significantly (0·37, 0·15-0·95, p=0·03). Treatment-related serious adverse events were infrequent. INTERPRETATION Although the reduction in stroke was not significant, our results support that in patients with recent lacunar stroke, the use of a systolic-blood-pressure target of less than 130 mm Hg is likely to be beneficial. FUNDING National Institutes of Health-National Institute of Neurological Disorders and Stroke (NIH-NINDS).
This paper references
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
S. Pinto (2001)
10.1161/01.STR.0000106480.76217.6F
Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History: The PROGRESS Trial
N. Chapman (2004)
10.1016/S0145-4145(08)79397-3
Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
W. Elliott (2009)
10.1056/NEJM200001203420301
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
S. Yusuf (2000)
10.1161/01.STR.0000092488.40085.15
Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review
P. Rashid (2003)
10.1056/NEJMoa1204133
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
O. Benavente (2012)
10.1161/HS1201.100209
Epidemiology of Ischemic Stroke Subtypes According to TOAST Criteria: Incidence, Recurrence, and Long-Term Survival in Ischemic Stroke Subtypes: A Population-Based Study
P. Kolominsky-Rabas (2001)
10.1097/MBP.0B013E3280858D5B
Reliability and validity of blood pressure measurement in the Secondary Prevention of Small Subcortical Strokes study
P. Pergola (2007)
Eff ects of intensive bloodpressure control in type 2 diabetes mellitus
WC Cushman (2010)
10.1016/S0513-5117(09)79045-3
Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke
A. Rabinstein (2009)
Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack
S. MacMahon (2001)
10.1161/01.STR.0000166048.35740.a9
Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES)
J. Schrader (2005)
Post-stroke antihypertensive treatment study. A preliminary result.
Pats (1995)
13 Hypertension-Stroke Cooperative Study Group Eff ect of antihypertensive treatment on stroke recurrence
(1974)
10.3109/08037059409102281
The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results.
L. Hansson (1994)
Eff ects of intensive blood-pressure control in type 2 diabetes mellitus
Wc Cushman (2010)
10.1161/01.STR.28.12.2557
Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators.
F. Gueyffier (1997)
10.1016/S0140-6736(11)60600-4
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
M. Bousser (2011)
10.1016/j.cct.2012.06.007
Sample size re-estimation in an on-going NIH-sponsored clinical trial: the secondary prevention of small subcortical strokes experience.
L. McClure (2012)
10.3109/08037059209077502
Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point.
L. Hansson (1992)
10.1056/NEJMoa1001286
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
W. Cushman (2010)
10.1159/000107813
Atenolol in Secondary Prevention after Stroke
S. Eriksson (1995)
Randomised trial of a perindoprilbased bloodpressurelowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
P Rashid (2001)
10.1161/CIRCULATIONAHA.109.934786
Declining Stroke and Vascular Event Recurrence Rates in Secondary Prevention Trials Over the Past 50 Years and Consequences for Current Trial Design
K. Hong (2011)
10.1111/j.1747-4949.2010.00573.x
The Secondary Prevention of Small Subcortical Strokes (SPS3) Study
O. Benavente (2011)
10.1056/NEJMoa1008816
Irbesartan in patients with atrial fibrillation.
S. Yusuf (2011)
10.1161/STR.0b013e3181f7d043
Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association.
K. Furie (2011)
10.1016/j.jstrokecerebrovasdis.2012.03.002
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial.
C. White (2013)
Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
S. Yusuf (2000)
10.1212/01.wnl.0000210457.89798.0e
A population-based study of the incidence and prognosis of lacunar stroke
S. Sacco (2006)
Eff ect of antihypertensive treatment on stroke recurrence
N Chapman (1974)
antihypertensive treatment on stroke recurrence
N Chapman (1974)
10.1161/STR.0000000000000024
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
W. Kernan (2014)
Post-stroke antihypertensive treatment study. A preliminary result
Pats-Collaborating-Group- (1995)
Clinical features and racial / ethnic diff erences among the 3020 participants in the secondary prevention of small subcortical strokes ( SPS 3 ) trial
L Hansson (2012)
Eff ects of an angiotensinconvertingenzyme inhibitor , ramipril , on cardiovascular events in high - risk patients
J Schrader (2000)
10.1007/S11886-001-0034-9
The Heart Outcomes Prevention Evaluation Study.
Kukin Ml (2001)



This paper is referenced by
10.1016/J.CCL.2019.04.006
Hypertension Management in Chronic Kidney Disease and Diabetes: Lessons from the Systolic Blood Pressure Intervention Trial.
G. Thomas (2019)
Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report
Paul A. James (2014)
10.1016/j.conctc.2018.100313
Impact of Department of Veterans Affairs Cooperative Studies Program clinical trials on practice guidelines for high blood pressure management
Adam M. Henrie (2019)
10.1007/978-3-319-39599-9_17
Follow-Up of the Hypertensive Patients with Cardiovascular Disease
Carmine Morisco (2016)
10.1161/CIR.0000000000000558
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
E. Benjamin (2018)
10.1161/jaha.118.008548
Nationwide Impact of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines on Stroke Survivors
Alain Lekoubou (2018)
10.1016/j.jacc.2014.04.066
Lower is not always better? Blood pressure treatment targets revisited.
C. Andersson (2014)
10.1161/CIRCRESAHA.116.309493
Is High Blood Pressure Self-Protection for the Brain?
E. Warnert (2016)
10.1016/j.jstrokecerebrovasdis.2015.12.027
Patterns and Predictors of Blood Pressure Treatment, Control, and Outcomes among Stroke Survivors in the United States.
A. Razmara (2016)
10.7812/TPP/14-226
2014 Hypertension Guideline: Recommendation for a Change in Goal Systolic Blood Pressure.
J. Handler (2015)
10.1080/14737175.2019.1623671
Intracerebral hemorrhage: an update on diagnosis and treatment
I. Hostettler (2019)
10.1038/s41397-018-0049-x
Genome-wide association analysis of common genetic variants of resistant hypertension
Nihal M. El Rouby (2018)
10.1016/S0140-6736(14)60182-3
Lessons from the SPS3 trial
Ricky D Turgeon (2014)
10.1097/HJH.0000000000001287
Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials
E. Atkins (2017)
10.1002/14651858.CD012825.PUB2
Anti-inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack.
Sarah Coveney (2020)
10.1001/jamaneurol.2017.5153
Effect of Standard vs Intensive Blood Pressure Control on Cerebral Blood Flow in Small Vessel Disease
I. Croall (2018)
10.1007/s11886-018-1063-y
Dangers of Overly Aggressive Blood Pressure Control
Faisal Rahman (2018)
10.1016/S0212-6567(16)30185-8
[Not Available].
Antonio Maiques Galán (2016)
Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot ’Prevention of Decline in Cognition after Stroke Trial’ (POD-
P. Bath (2018)
10.7326/M18-1037
Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction
William R. Zhang (2018)
10.1007/s00508-019-01565-0
[Austrian Consensus on High Blood Pressure 2019].
T. Weber (2019)
10.1161/CIR.0000000000000350
Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
D. Mozaffarian (2016)
10.2147/DNND.S37353
Poststroke cognitive impairment and dementia: prevalence, diagnosis, and treatment
S. Melkas (2014)
10.1080/14779072.2020.1732206
Managing the elderly patient with hypertension: current strategies, challenges, and considerations
W. S. Aronow (2020)
10.1097/HJH.0000000000000929
Awareness, treatment, and control of hypertension in Austria: a multicentre cross-sectional study
M. Rohla (2016)
10.1016/S1474-4422(14)70180-2
Blood pressure control after stroke: too little, too late, or too soon to tell?
Argye E. Hillis (2014)
10.1016/S0140-6736(17)30754-7
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials
M. Böhm (2017)
10.1136/svn-2016-000035
Update on cerebral small vessel disease: a dynamic whole-brain disease
Y. Shi (2016)
10.1016/J.NEFROE.2018.05.003
Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a Nephrology outpatient clinic.
Isabel Galán (2018)
10.6515/ACS20170421A
The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension.
C. Chiang (2017)
10.1007/s12170-017-0548-3
Managing Hypertension in the Elderly: What is Different, What is the Same?
Wilbert S Aronow (2017)
10.1016/j.medcli.2016.11.029
Which antihypertensive drug should be used in patients with cerebrovascular disease to prevent a new stroke?
Luis Castilla-Guerra (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar